Skip to main content

Postmenopausal Osteoporosis

23
Pipeline Programs
24
Companies
30
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
3
0
7
9
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
4100%
+ 38 programs with unclassified modality

Competitive Landscape

24 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
7 programs
5
AlendronatePhase 41 trial
IbandronatePhase 41 trial
IbandronatePhase 41 trial
IbandronatePhase 41 trial
ibandronate [Bonviva/Boniva]Phase 41 trial
+2 more programs
Active Trials
NCT01128257Completed6,054Est. Dec 2011
NCT00493532No Longer AvailableEst. Dec 2010
NCT02598440Completed341Est. May 2005
+4 more trials
Prevail Therapeutics
3 programs
3
TeriparatidePhase 4Peptide
TeriparatidePhase 4Peptide
teriparatidePhase 4Peptide
Dong-A ST
Dong-A STKorea - Seoul
1 program
1
Risedronate Sodium 35 MG [Actonel]Phase 41 trial
Active Trials
NCT05630768Completed149Est. Jul 2025
Sandoz
SandozAustria - Kundl
4 programs
3
1
Zoledronic acidPhase 31 trial
Oral salmon calcitoninPhase 11 trial
Oral salmon calcitonin, salmon calcitonin nasal sprayPhase 11 trial
PTH134Phase 11 trial
Active Trials
NCT00411125Completed86Est. Nov 2006
NCT00395395Completed56
NCT00676312Completed32
+1 more trials
Luye Pharma
Luye PharmaChina - Shanghai
1 program
1
LY06006Phase 31 trial
Active Trials
NCT05060406Unknown448Est. Dec 2021
MSD
MSDIreland - Ballydine
1 program
1
OdanacatibPhase 31 trial
Active Trials
NCT00529373Terminated16,071Est. Feb 2017
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
OdanacatibPhase 3
Samsung Bioepis
Samsung BioepisKorea - Incheon
1 program
1
SB16Phase 31 trial
Active Trials
NCT04664959Completed457Est. Jan 2023
Chiesi
ChiesiBrazil - Santana de Parnaíba
1 program
1
disodium clodronate 200 mg/4 ml with 1% lidocainePhase 31 trial
Active Trials
NCT01348243Completed260Est. Mar 2013
Alvogen
AlvogenNJ - Morristown
1 program
1
ibandronatePhase 3
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
BazedoxifenePhase 21 trial
Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mgPhase 11 trial
Active Trials
NCT00381251CompletedEst. Jan 2007
NCT00238745Completed375Est. Mar 2007
Biocorp
BiocorpFrance - Issoire
1 program
1
JMT103Phase 21 trial
Active Trials
NCT05278338Unknown200Est. Mar 2024
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
PTH analogPhase 2
Roche
RocheSTAVANGER NORWAY, Norway
4 programs
Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in PakistanN/A
alendronateN/A
ibandronate [Bonviva/Boniva]N/A
ibandronate [Bonviva/Boniva]PHASE_4
Radius Health
Radius HealthMA - Boston
3 programs
abaloparatide-sMTSPHASE_11 trial
AlendronatePHASE_31 trial
abaloparatidePHASE_3Peptide1 trial
Active Trials
NCT04366726Completed22Est. May 2019
NCT01657162Completed1,139Est. Oct 2016
NCT04064411Completed511Est. Nov 2021
Novartis
NovartisBASEL, Switzerland
2 programs
Oral salmon calcitoninPHASE_1
PTH134PHASE_1
Chugai Pharma
Chugai PharmaJapan - Tokyo
1 program
Eldecalcitol soft capsulesN/A1 trial
Active Trials
NCT05433207Unknown1,000Est. Jan 2025
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Integrated Osteoporosis CareN/A1 trial
Active Trials
NCT03970902Completed239Est. Apr 2022
Enzene Biosciences
Enzene BiosciencesIndia - Pune
1 program
ENZ215PHASE_31 trial
Active Trials
NCT05405725Completed504Est. Jul 2024
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
FKS518PHASE_31 trial
Active Trials
NCT04934072Completed553Est. Aug 2023
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
QL1206PHASE_31 trial
Active Trials
NCT04128163Unknown440Est. Dec 2021
Gedeon Richter
Gedeon RichterHungary - Budapest
1 program
RGB-14-PPHASE_31 trial
Active Trials
NCT05087030Completed473Est. Nov 2023
Eisai
EisaiChina - Liaoning
1 program
menatetranonePHASE_31 trial
Active Trials
NCT00165698Completed240Est. Jul 2007
Sanofi
SanofiPARIS, France
1 program
risedronatePHASE_31 trial
Active Trials
NCT00577421Completed32Est. Jan 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dong-A STRisedronate Sodium 35 MG [Actonel]
GenentechIbandronate
Genentechibandronate [Bonviva/Boniva]
GenentechIbandronate
GenentechIbandronate
GenentechAlendronate
Enzene BiosciencesENZ215
Gedeon RichterRGB-14-P
Fresenius KabiFKS518
Samsung BioepisSB16
Radius Healthabaloparatide
Luye PharmaLY06006
Qilu PharmaceuticalQL1206
Radius HealthAlendronate
Chiesidisodium clodronate 200 mg/4 ml with 1% lidocaine

Showing 15 of 30 trials with date data

Clinical Trials (30)

Total enrollment: 33,357 patients across 30 trials

NCT05630768Dong-A STRisedronate Sodium 35 MG [Actonel]

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Start: Jan 2023Est. completion: Jul 2025149 patients
Phase 4Completed

A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)

Start: Apr 2006Est. completion: Jan 2008716 patients
Phase 4Completed
NCT00545909Genentechibandronate [Bonviva/Boniva]

BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis

Start: Mar 2006Est. completion: Aug 2008585 patients
Phase 4Completed

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

Start: Jan 2005Est. completion: Sep 2006545 patients
Phase 4Completed

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

Start: Jun 2004Est. completion: Apr 20061,711 patients
Phase 4Completed

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

Start: Mar 2004Est. completion: May 2005341 patients
Phase 4Completed

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

Start: Jul 2022Est. completion: Jul 2024504 patients
Phase 3Completed

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

Start: Sep 2021Est. completion: Nov 2023473 patients
Phase 3Completed

A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

Start: Jun 2021Est. completion: Aug 2023553 patients
Phase 3Completed

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Start: Nov 2020Est. completion: Jan 2023457 patients
Phase 3Completed

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Start: Aug 2019Est. completion: Nov 2021511 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Start: Jun 2019Est. completion: Dec 2021448 patients
Phase 3Unknown

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

Start: Jun 2019Est. completion: Dec 2021440 patients
Phase 3Unknown

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Start: Nov 2012Est. completion: Oct 20161,139 patients
Phase 3Completed
NCT01348243Chiesidisodium clodronate 200 mg/4 ml with 1% lidocaine

Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis

Start: Oct 2011Est. completion: Mar 2013260 patients
Phase 3Completed
NCT00909961SandozZoledronic acid

A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years

Start: Nov 2009Est. completion: Dec 2011118 patients
Phase 3Completed
NCT00529373MSDOdanacatib

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Start: Sep 2007Est. completion: Feb 201716,071 patients
Phase 3Terminated
NCT00165698Eisaimenatetranone

Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

Start: May 2005Est. completion: Jul 2007240 patients
Phase 3Completed

Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO

Start: Jun 2003Est. completion: Jan 200632 patients
Phase 3Completed

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Start: Apr 2022Est. completion: Mar 2024200 patients
Phase 2Unknown
NCT00238745PfizerBazedoxifene

Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

Start: Aug 2003Est. completion: Mar 2007375 patients
Phase 2Completed
NCT04366726Radius Healthabaloparatide-sMTS

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

Start: Apr 2019Est. completion: May 201922 patients
Phase 1Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects

Start: May 200832 patients
Phase 1Completed
NCT00395395SandozOral salmon calcitonin, salmon calcitonin nasal spray

Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Start: Oct 200656 patients
Phase 1Completed
NCT00381251PfizerFormulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg

Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.

Start: Sep 2006Est. completion: Jan 2007
Phase 1Completed
NCT00411125SandozOral salmon calcitonin

Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Start: Aug 2006Est. completion: Nov 200686 patients
Phase 1Completed
NCT05433207Chugai PharmaEldecalcitol soft capsules

Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis

Start: Aug 2022Est. completion: Jan 20251,000 patients
N/AUnknown
NCT03970902AmgenIntegrated Osteoporosis Care

Quality of Life in Postmenopausal Women With Osteoporosis

Start: Jul 2019Est. completion: Apr 2022239 patients
N/ACompleted

A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis

Start: Apr 2010Est. completion: Dec 20116,054 patients
N/ACompleted
NCT00493532Genentechibandronate [Bonviva/Boniva]

A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Start: Jun 2007Est. completion: Dec 2010
N/ANo Longer Available

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals
24 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.